480 related articles for article (PubMed ID: 29150328)
1. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
[TBL] [Abstract][Full Text] [Related]
2. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Goldwater R; Hussaini A; Bosch B; Nemeth P
Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
[TBL] [Abstract][Full Text] [Related]
6. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
7. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
8. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
9. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Ohlmann CH; Jäschke M; Jaehnig P; Krege S; Gschwend J; Rexer H; Stöckle M
Trials; 2017 Oct; 18(1):457. PubMed ID: 28978327
[TBL] [Abstract][Full Text] [Related]
11. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
12. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract][Full Text] [Related]
13. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
[TBL] [Abstract][Full Text] [Related]
14. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.
Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; De Porre P; Vermeulen A; Poggesi I; Nandy P
Clin Pharmacokinet; 2017 Jan; 56(1):55-63. PubMed ID: 27324190
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
16. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
17. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ
Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838
[TBL] [Abstract][Full Text] [Related]
20. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
